Edition:
India

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

12.78USD
1:30am IST
Change (% chg)

$0.21 (+1.67%)
Prev Close
$12.57
Open
$12.47
Day's High
$12.90
Day's Low
$12.35
Volume
182,763
Avg. Vol
283,529
52-wk High
$16.59
52-wk Low
$5.14

Latest Key Developments (Source: Significant Developments)

Epizyme Submits New Drug Application To FDA For Cancer Treatment
Thursday, 30 May 2019 

May 30 (Reuters) - Epizyme Inc ::EPIZYME SUBMITS NEW DRUG APPLICATION TO THE U.S. FDA FOR TAZEMETOSTAT FOR THE TREATMENT OF PATIENTS WITH EPITHELIOID SARCOMA.EPIZYME INC - SUBMISSION FOLLOWS PRODUCTIVE PRE-NDA MEETING AND MARKS ON-TIME EXECUTION OF FIRST OF TWO NDA SUBMISSIONS PLANNED FOR 2019.EPIZYME INC - EPIZYME PLANS TO CONDUCT A GLOBAL, RANDOMIZED, CONTROLLED TRIAL, THAT IT EXPECTS TO BEGIN IN SECOND HALF OF 2019..  Full Article

Epizyme Reports Q1 Loss Per Share At $0.39
Monday, 6 May 2019 

May 6 (Reuters) - Epizyme Inc ::EPIZYME PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.39.Q1 EARNINGS PER SHARE ESTIMATE $-0.46 -- REFINITIV IBES DATA.TAZEMETOSTAT NDA SUBMISSIONS FOR EPITHELIOID SARCOMA AND FOLLICULAR LYMPHOMA ON TRACK FOR Q2 AND Q4 2019, RESPECTIVELY.UPDATED DATA FROM TAZEMETOSTAT DEVELOPMENT PROGRAM TO BE PRESENTED IN Q2.COLLABORATION REVENUE FOR Q1 OF 2019 WAS $7.9 MILLION.INCREASE IN COLLABORATION REVENUE IN Q1 IS DUE TO COLLABORATION WITH BOEHRINGER INGELHEIM, WHICH WAS INITIATED IN NOV 2018.EXPECTS CASH RUNWAY TO EXTEND INTO AT LEAST Q1 OF 2021.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $371.1 MILLION AS OF MARCH 31 VERSUS $247.9 MILLION AS OF MARCH 31, 2018.Q1 EARNINGS PER SHARE VIEW $-0.46, REVENUE VIEW $2.2 MILLION -- REFINITIV IBES DATA.  Full Article

Epizyme Announces Pricing Of Concurrent Public Offerings Of Common Stock And Series A Preferred Stock
Thursday, 7 Mar 2019 

March 6 (Reuters) - Epizyme Inc ::EPIZYME ANNOUNCES PRICING OF CONCURRENT PUBLIC OFFERINGS OF COMMON STOCK AND SERIES A PREFERRED STOCK.EPIZYME - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 10 MILLION SHARES OF COMMON STOCK.PUBLIC OFFERING PRICE OF EACH SHARE OF COMMON STOCK IS $11.50 AND PUBLIC OFFERING PRICE OF EACH SHARE OF SERIES A STOCK IS $115.00.ALSO PRICED UNDERWRITTEN PUBLIC OFFERING OF 304,348 SHARES OF ITS NON-VOTING SERIES A CONVERTIBLE PREFERRED STOCK.  Full Article

Epizyme Earns $8 Mln Milestone Payment From Glaxosmithkline For Initiation Of Clinical Development For First-In-Class Prmt1 Inhibitor
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Epizyme Inc ::EPIZYME EARNS $8 MILLION MILESTONE PAYMENT FROM GLAXOSMITHKLINE FOR INITIATION OF CLINICAL DEVELOPMENT FOR FIRST-IN-CLASS PRMT1 INHIBITOR.EPIZYME INC - CO GRANTED GSK EXCLUSIVE WORLDWIDE LICENSE RIGHTS TO METHYLTRANSFERASE INHIBITORS DIRECTED TO 3 TARGETS.EPIZYME INC - EARNED AGGREGATE OF $89 MILLION IN UP-FRONT, RESEARCH & MILESTONE PAYMENTS TO DATE.EPIZYME INC - MAY RECEIVE UPTO ADDITIONAL $375 MILLION FROM GSK IF ALL REMAINING MILESTONES ARE MET.EPIZYME INC - ELIGIBLE TO RECEIVE UP TO DOUBLE-DIGIT ROYALTIES ON WORLDWIDE NET SALES OF COLLABORATION PRODUCTS.  Full Article

Epizyme Reports Q3 EPS of $0.54 Per Share
Friday, 2 Nov 2018 

Nov 2 (Reuters) - Epizyme Inc ::EPIZYME REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND TAZEMETOSTAT PROGRESS.Q3 LOSS PER SHARE $0.54.Q3 EARNINGS PER SHARE VIEW $-0.61 -- THOMSON REUTERS I/B/E/S.RESEARCH AND DEVELOPMENT EXPENSES WERE $27.0 MILLION FOR Q3 OF 2018, WHICH COMPARES TO $28.7 MILLION FOR Q3 OF 2017.EXPECTS EXISTING CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND ITS PLANNED OPERATIONS INTO Q1 OF 2020.ENROLLMENT IN PHASE 2 COHORT OF FOLLICULAR LYMPHOMA PATIENTS WITH EZH2 ACTIVATING MUTATIONS ON TRACK TO BE COMPLETED BY YEAR END.RECENT FINANCING EXTENDS OPERATING RUNWAY INTO Q1 OF 2020.EPIZYME - UPDATED EFFICACY & SAFETY DATA FOR TAZEMETOSTAT IN EPITHELIOID SARCOMA SUPPORT CO'S PLANNED SUBMISSION OF NEW DRUG APPLICATION IN H1 OF 2019.  Full Article

Epizyme Says Positive Data On Tazemetostat In Epithelioid Sarcoma From Phase 2 Trial Cohort At ESMO
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Epizyme Inc ::EPIZYME REPORTS POSITIVE DATA ON TAZEMETOSTAT IN EPITHELIOID SARCOMA FROM ITS PHASE 2 TRIAL COHORT AT ESMO.EPIZYME - UPDATED EFFICACY, SAFETY DATA SUPPORT CO'S PLANNED SUBMISSION OF A NEW DRUG APPLICATION FOR TAZEMETOSTAT FOR EPITHELIOID SARCOMA IN H1 2019.  Full Article

Epizyme Announces Pricing Of Public Offering Of Common Stock
Wednesday, 3 Oct 2018 

Oct 2 (Reuters) - Epizyme Inc ::EPIZYME ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.33 MILLION COMMON SHARES PRICED AT $9.00PER SHARE.  Full Article

Epizyme Announces Proposed Public Offering Of Common Stock
Wednesday, 3 Oct 2018 

Oct 2 (Reuters) - Epizyme Inc ::EPIZYME ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.EPIZYME - TO USE PROCEEDS FROM OFFERING, TO FUND GLOBAL DEVELOPMENT COMMERCIALIZATION COSTS OF TAZEMETOSTAT OUTSIDE OF JAPAN.  Full Article

Epizyme Says U.S. FDA Lifted Partial Clinical Hold On Tazemetostat Clinical Program
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Epizyme Inc ::EPIZYME ANNOUNCES THE U.S. FOOD AND DRUG ADMINISTRATION LIFTS PARTIAL CLINICAL HOLD ON TAZEMETOSTAT CLINICAL PROGRAM.EPIZYME INC - CO IS NOW IN PROCESS OF REOPENING ENROLLMENT IN ALL OF ITS COMPANY-SPONSORED TRIALS IN U.S..EPIZYME INC - WILL NOW ENGAGE WITH REGULATORS IN FRANCE AND GERMANY TO RESOLVE PARTIAL CLINICAL HOLDS AND RESUME ENROLLMENT IN THOSE COUNTRIES.  Full Article

Epizyme Reports Q2 Loss Per Share $0.42
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Epizyme Inc ::EPIZYME REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q2 LOSS PER SHARE $0.42.Q2 REVENUE $12 MILLION VERSUS $10 MILLION.Q2 REVENUE VIEW $538,000 -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S.  Full Article